Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Bioorg Med Chem Lett. 2021 Jul 1;43:128081. doi: 10.1016/j.bmcl.2021.128081. Epub 2021 May 5.
In our continuing efforts to develop novel neuroprotectants for Alzheimer's disease (AD), a series of analogs based on a lead compound that was recently shown to target the mitochondrial complex I were designed, synthesized and biologically characterized to understand the structure features that are important for neuroprotective activities. The results from a cellular AD model highlighted the important roles of the 4-OH on the phenyl ring and the 5-OCH on the indole ring of the lead compound. The results also demonstrated that the β-keto moiety can be modified to retain or improve the neuroprotective activity. Docking studies of selected analogs to the FMN site of mitochondrial complex I also supported the observed neuroprotective activities. Collectively, the results provide further information to guide optimization and development of analogs based on this chemical scaffold as neuroprotectants with a novel mechanism of action for AD.
在我们不断努力开发新型阿尔茨海默病(AD)神经保护剂的过程中,设计、合成并对一系列基于最近被证明可靶向线粒体复合物 I 的先导化合物的类似物进行了生物学特征分析,以了解对神经保护活性很重要的结构特征。来自细胞 AD 模型的结果突出了先导化合物中苯环上的 4-OH 和吲哚环上的 5-OCH 的重要作用。结果还表明,β-酮部分可以修饰以保留或提高神经保护活性。对线粒体复合物 I 的黄素单核苷酸(FMN)结合位点进行的选定类似物的对接研究也支持了观察到的神经保护活性。总的来说,这些结果提供了进一步的信息,以指导基于该化学支架的类似物的优化和开发,作为具有新型作用机制的 AD 神经保护剂。